Skip to main content
Clinical Trials/ISRCTN13400668
ISRCTN13400668
Completed
Phase 1

A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis

niversity Hospital Southampton NHS Foundation Trust0 sites10 target enrollmentNovember 15, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Systemic AL-Amyloidosis
Sponsor
niversity Hospital Southampton NHS Foundation Trust
Enrollment
10
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 15, 2016
End Date
July 7, 2020
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity Hospital Southampton NHS Foundation Trust

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged \=18 years
  • 2\. Diagnosis of systemic AL\-amyloidosis, either as a new diagnosis or recurrent disease
  • 3\. Measurable clonal plasma cell dyscrasia
  • 4\. Amyloid related organ dysfunction or organ syndrome
  • 5\. Estimated life expectancy of at least 6 months (as defined at trial entry)
  • 6\. Sufficient stem cells for two transplant procedures
  • 7\. Bone Marrow (BM) cellularity \>20%
  • 8\. Eligible for ASCT in AL amyloidosis defined as fulfilling all of the following criteria:
  • 8\.1\. ECOG Performance Status of 0 or 1
  • 8\.2\. Cardiac troponin\-T \<0\.07 µg/L

Exclusion Criteria

  • 1\. Overt symptomatic multiple myeloma
  • 2\. Amyloidosis of unknown or non AL type
  • 3\. Localised AL\-amyloidosis (in which amyloid deposits are limited to a typical single organ, for example the bladder or larynx, in association with a clonal proliferative disorder within that organ)
  • 4\. Trivial or incidental AL amyloid deposits in the absence of a significant amyloid related organ syndrome (e.g., isolated carpal tunnel syndrome)
  • 5\. NYHA Class III or IV heart failure
  • 6\. Liver involvement by amyloid causing bilirubin \>1\.5 times upper limit of normal
  • 7\. Concurrent active malignancies, except surgically removed basal cell carcinoma of the skin or other in situ carcinomas
  • 8\. Pregnant, lactating or unwilling to use adequate contraception
  • 9\. Intolerance / sensitivity to any of the study drugs
  • 10\. Known positive Human anti\-murine antibodies (HAMA)

Outcomes

Primary Outcomes

Not specified

Similar Trials